MedTrace Logo

Paroxetine Versus Placebo for Vasomotor Symptom Management in Surgical Menopause

NCT06763484 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-09-17

No results posted yet for this study

Summary

evaluate the efficacy of paroxetine in the management of vasomotor symptoms in patients with surgical menopause, in order to seek an alternative therapy to hormone therapy, which is associated with proinflammatory and procoagulant effects that increase the risk of thrombosis and is therefore contraindicated in people with diabetes mellitus, chronic arterial hypertension and patients with a history of thromboembolism

Conditions

Interventions

DRUG

Paroxetine

20 mg PO daily

DIETARY_SUPPLEMENT

Placebo

1 capsule starch

Sponsors & Collaborators

  • Universidad Nacional Autonoma de Honduras

    lead OTHER

Principal Investigators

  • Ricardo A. Gutierrez Ramirez · Universidad Nacional Autonoma de Honduras

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-30
Primary Completion
2025-07-31
Completion
2025-09-01

Countries

  • Honduras

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06763484 on ClinicalTrials.gov